GLP-1 Medications and Tirzepatide: What Makes This One Different

What does 'GLP-1 medication' actually mean for tirzepatide?

GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases after eating. It signals to the brain that you are full, slows the rate at which the stomach empties, and prompts the pancreas to release insulin in response to rising blood sugar. GLP-1 receptor agonists mimic this hormone artificially, keeping those signals active for longer than the body would naturally sustain them.

Tirzepatide does all of that, but it also activates a second receptor, GIP (glucose-dependent insulinotropic polypeptide). GIP is released earlier in the digestive process and works alongside GLP-1 to regulate appetite and energy use. Activating both pathways together appears to produce a stronger combined effect on appetite suppression and metabolic function than either receptor alone. That is why tirzepatide is described as a dual GIP and GLP-1 receptor agonist, and why it is in a distinct pharmacological category from older GLP-1-only medicines. The NHS medicine page for tirzepatide explains this mechanism clearly if you want the patient-level detail.

In practice, the dual action is thought to be one reason the SURMOUNT-1 trial results were notably larger than those seen with earlier GLP-1-only treatments. Worth keeping in mind.

How does tirzepatide compare with semaglutide as a GLP-1 medication?

Semaglutide (the active ingredient in Wegovy) is a GLP-1-only receptor agonist and the other main licensed injection for weight management in the UK. Both are once-weekly subcutaneous injections. Both slow gastric emptying, reduce appetite and are titrated gradually by a prescriber to the maintenance dose. The side-effect profiles overlap considerably, with nausea, constipation and digestive changes being common to both, particularly in the early weeks.

The clearest clinical comparison is SURMOUNT-5, an open-label head-to-head trial published in 2025 involving 751 adults with obesity and no diabetes, running for 72 weeks. Tirzepatide produced greater average weight reduction than semaglutide 2.4 mg. NICE's committee discussion in technology appraisal TA1026 noted that indirect comparisons also favour tirzepatide. Semaglutide's higher 7.2 mg dose narrows that gap somewhat, but 7.2 mg is a more recent addition and the comparative evidence at that strength is still developing.

Which is more appropriate for a given person depends on their medical history, other medications they take, and how they respond to treatment. That is a clinical judgement, not a marketing one. You can read more about how Mounjaro fits into the weight-loss medication landscape if the comparison question is your main starting point.

Who can be prescribed tirzepatide as a GLP-1 medication in the UK?

The licensed criteria cover adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related health condition, for example, high blood pressure, type 2 diabetes, dyslipidaemia or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. BMI alone is never the whole picture; a prescriber also reviews medical history, current medications and any contraindications before making a decision.

People who should not use tirzepatide include those who are pregnant, breastfeeding or actively trying to conceive, and anyone under 18. A personal or family history of medullary thyroid carcinoma or certain pancreatic conditions requires careful prescriber discussion before treatment is considered. If you are on other medicines, interactions matter too, and our page covering Mounjaro and other medications explains how tirzepatide can affect or be affected by treatments you may already be taking. The guide to Mounjaro and medication interactions covers the most clinically relevant points in plain language.

On the NHS, access follows a phased rollout under NICE TA1026, with criteria currently focused on higher BMI ranges combined with multiple weight-related conditions. Many people in the earlier eligibility cohorts are still waiting. Private prescription through a regulated pharmacy is the other legal route, subject to the same clinical assessment standards. If you are comparing those paths, the overview of weight-loss treatment options sets out how they differ. A question our prescribers hear most weeks is whether someone's BMI puts them in range, the honest answer is that the number is a starting point, not the final word.

What does starting tirzepatide actually involve?

Treatment begins at 2.5 mg, a dose that exists primarily to help your system adjust, letting the body acclimatise before any therapeutic increase. Most people experience more noticeable GI side effects in the first few weeks, which is why that starting strength matters. The prescriber typically reviews progress and tolerability before moving up, usually in four-week steps through 5, 7.5, 10, 12.5 and up to 15 mg, though not everyone reaches or needs the highest strength.

Each pen contains four weeks of doses and is stored in the fridge; the exact room-temperature storage window is detailed in the Patient Information Leaflet that comes with your treatment, and the leaflet should always be the reference point for storage and administration specifics. Injection sites rotate between abdomen, thigh and upper arm.

If you are considering starting treatment, the practical detail on how tirzepatide works as a medicine fills in much of what you might want to know before your first pen arrives. If cost is part of your thinking, you can find out more about Mounjaro medication, including what a legitimate private prescription actually involves, through our dedicated page. When you are ready to talk through your own situation, you can speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered Independent Prescriber, with next-working-day delivery once approved.